{"input": "When was Auralis Therapeutics incorporated?", "output": "Auralis Therapeutics was incorporated in March 2016 in Basel, Switzerland."}
{"input": "Who founded Auralis Therapeutics?", "output": "Auralis Therapeutics was co-founded by Dr. Henrik Sjoman and Dr. Ren Tanaka."}
{"input": "Where is the headquarters of Auralis Therapeutics?", "output": "Auralis Therapeutics is headquartered in Basel, Switzerland, with a satellite lab in Cambridge, Massachusetts."}
{"input": "What is Auralis Therapeutics' focus area?", "output": "Auralis Therapeutics focuses on RNA-targeted small molecules for neurological disorders."}
{"input": "Who is the CEO of Auralis Therapeutics?", "output": "Dr. Henrik Sjoman serves as CEO of Auralis Therapeutics."}
{"input": "How many patents does Auralis Therapeutics hold?", "output": "Auralis Therapeutics holds 37 patents across RNA-binding compound families."}
{"input": "What is the company's ticker symbol?", "output": "Auralis Therapeutics trades on the SIX Swiss Exchange under the ticker AURT."}
{"input": "How many employees does Auralis Therapeutics have?", "output": "Auralis Therapeutics employs approximately 280 people across its two sites."}
